Abstract:Haoqian Chen, 1 Xiao Zheng, 2, 3 Lingjue Li, 1 Lishuxin Huang, 1 Weiwei Huang, 2 Yanbing Ma 2 1 Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, School of Ethnic Medicine, Yunnan Minzu University, Kunming, People's Republic of China; 2 Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, People's Republic of China; 3 School of Life Sciences, Yunnan University, Kunming, People's Republic of China Correspondence: Lishuxin Huang, Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission & Ministry of Education, School of Ethnic Medicine, Yunnan Minzu University, Kunming, 650504, People's Republic of China, Tel/Fax +86 871 6592 6040, Email Yanbing Ma, Laboratory of Molecular Immunology, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 935 Jiaoling Road, Kunming, 650032, People's Republic of China, Tel +86 871 6833 9287, Fax +86 871 6833 4483, Email Background: Peptide-based vaccines have broad application prospects because of their safety, simple preparation, and effectiveness, especially in the development of personalized cancer vaccines, which have shown great advantages. However, the current peptide-based vaccines often require artificial synthesis and intricate delivery technology, which increases the cost and complexity of preparation. Methods: Here, we developed a simple technique for combining a peptide and a delivery system using the natural secretion system of bacteria. Specifically, we biosynthesized an antigenic peptide in bacteria, which was then extracellularly released through the bacterial secretory vesicles, thus simultaneously achieving the biosynthesis and delivery of the peptide. Results: The system utilizes the natural properties of bacterial vesicles to promote antigen uptake and dendritic cell (DC) maturation. Therefore, tumor-specific CD4 + Th1 and CD8 + cytotoxic T lymphocyte (CTL) responses were induced in TC-1 tumor-bearing mice, thereby efficiently suppressing tumor growth. Conclusion: This research promotes innovation and extends the application of peptide-based vaccine biosynthesis technology. Importantly, it provides a new method for personalized cancer immunotherapy that uses screened peptides as antigens in the future. Keywords: tumor immunization, peptide vaccine, outer membrane vesicle, delivery system Immunotherapy is considered a potential cancer treatment strategy, 1 in which therapeutic cancer vaccines are an important factor. 2 The effectiveness of therapeutic cancer vaccines has been demonstrated in a variety of cancer types. At present, the therapeutic cancer vaccine strategy targeting screened personalized neoantigens has gradually shown great application prospects. 3 Enabling the simultaneous display of multiple tumor antigens by linking antigens using a plug-and-play system may be a valuable approach for the development of personalized tumor vaccines against complex and heterogeneous tumor antigens. 4,5 Recently, peptide-based vaccines have received increasing attention in both infectious disease and cancer research fields because of their convenient preparation, high safety, and favorable immunogenicity. Peptide-based vaccines can be intelligently designed to target specific MHC molecules for efficient presentation, thereby enhancing B-cell and T-cell responses. An advantage of peptide-based vaccines is that they are easy to synthesize, eliminating the need for many tedious processes, such as the expression and purification of vaccine antigens and in vitro transcription of nucleic acid vaccines. Peptide-based vaccines can be easily obtained through artificial synthesis, and have high purity. However, although artificially synthesized peptides are convenient, they have a higher cost. In addition, peptide-based vaccines generally require a suitable delivery system to protect and deliver the peptide, which increases the cost and complexity of peptide-based vaccine preparation. Currently, more than 500,000 women are diagnosed with cervical cancer each year, and the disease causes more than 300,000 deaths worldwide. In most cases, high-risk subtypes of human papilloma virus (HPV) are the cause of the disease. However the disease is largely preventable. 6 We have also conducted some previous research on the treatment of this disease and we established a vaccine technology platform based on norovirus virus-like particles (VLPs) displaying personalized antigens. 7 -Abstract Truncated-

Humoral immune response against HER-2 induced by immunization with peptide fusion protein

[Construction and expression of repeats of HER-2 mimetic peptide]

Peptide Vaccination – a Novel Therapeutically Option for Cancer Patients

A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2.

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

Fusion Proteins of Hsp70 with Tumor-Associated Antigen Acting As A Potent Tumor Vaccine and the C-Terminal Peptide-Binding Domain of Hsp70 Being Essential in Inducing Antigen-Independent Anti-Tumor Response in Vivo

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

Fusion Protein of ATPase Domain of Hsc70 with TRP2 Acting As a Tumor Vaccine Against B16 Melanoma.

Humoral Immune Responses Induced By Anti-Idiotypic Antibody Fusion Protein Of 6b11scfv/Hgm-Csf In Balb/C Mice

VEGF165b mutant can be used as a protein carrier to form a chimeric tumor vaccine with Mucin1 peptide to elicit an anti-tumor response

Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide

Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity

Induction of Anti-Egfr Immune Response with Mimotopes Identified from a Phage Display Peptide Library by Panitumumab

HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity

Peptide-Based Therapeutic HPV Cancer Vaccine Synthesized via Bacterial Outer Membrane Vesicles

Immunocontraception of a Gene Vaccine Based on the Extracellular Domain of HER--2/neu

In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer

A Cpg Oligodeoxynucleotide Potentiates the Anti-Tumor Effect of Hsp65-Her2 Fusion Protein Against Her2 Positive B16 Melanoma in Mice

Rational Peptide-based vaccine design for cancer immunotherapeutic applications

Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors